Algorithm-Based Strategies for Opioid Use Disorder

Overseen by Jessica Merlin

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Pittsburgh

No Placebo Group

Trial Summary

What is the purpose of this trial?

The NIH Helping to End Addiction Long-term (HEAL) initiative has identified a critical next step to addressing the opioid crisis: improving treatments for opioid misuse behaviors (e.g., using more opioids than prescribed, illicit substance use) in patients prescribed long-term opioid therapy for chronic pain. In previous work, the investigators have developed innovative consensus-based algorithms to manage these behaviors. By developing implementation strategies for these algorithms, this project is directly responsive to the HEAL initiative and promises to reduce opioid misuse-related harms.

Research Team

Jessica Merlin

Principal Investigator

University of Pittsburgh

Eligibility Criteria

This trial is for individuals who are prescribed long-term opioid therapy (LTOT) for chronic pain and exhibit opioid misuse behaviors. Participants must be from UPMC community primary care practices. Those from non-UPMC practices cannot participate.

Inclusion Criteria

UPMC community primary care practices

Exclusion Criteria

This criterion excludes individuals who do not receive medical care from UPMC (University of Pittsburgh Medical Center) practices.

Treatment Details

Interventions

• Pilot study of algorithms implementation package (Behavioral Intervention)

Trial Overview The study tests a new approach to reduce opioid misuse by implementing consensus-based algorithms in healthcare settings. It's part of the NIH HEAL initiative aimed at improving treatments for patients with opioid use issues on LTOT.

Participant Groups

Group I: Implementation bundle Experimental Treatment 1 Intervention

Participating clinics will experience integration of the "Implementation Bundle" into their practices.

Who Is Running the Clinical Trial?

University of Pittsburgh

Lead Sponsor

Trials

1,820

Recruited

16,360,000+

David Apelian

University of Pittsburgh

Chief Executive Officer since 2019

PhD in Molecular Biology from Rutgers University, MD from the University of Medicine and Dentistry of New Jersey, MBA from Quinnipiac University

Pamela D. Garzone

University of Pittsburgh

Chief Medical Officer

PhD in Clinical Science from the University of Pittsburgh

National Institute on Drug Abuse (NIDA)

Collaborator

Trials

2,658

Recruited

3,409,000+

Dr. Nora Volkow

National Institute on Drug Abuse (NIDA)

Chief Executive Officer since 2003

MD from National Autonomous University of Mexico

Dr. Nora Volkow

National Institute on Drug Abuse (NIDA)

Chief Medical Officer since 2003

MD from National Autonomous University of Mexico